Welcome to our dedicated page for Procter & Gamble SEC filings (Ticker: PG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Procter & Gamble Company (PG) files a wide range of documents with the U.S. Securities and Exchange Commission, providing detailed insight into its operations, capital structure, governance, and shareholder policies. As a New York Stock Exchange‑listed issuer with common stock and multiple series of notes registered under Section 12(b) of the Exchange Act, P&G uses SEC filings to report material events, financing activities, executive and director matters, and shareholder meeting results.
Recent Form 8‑K filings illustrate the types of information investors can find. Regulation FD 8‑Ks document quarterly dividend declarations on common stock and ESOP convertible preferred stock, along with the company’s long record of consecutive dividend payments and increases. Other 8‑Ks report underwritten public offerings of U.S. dollar, euro, and pound sterling notes with various maturities, including floating rate notes and fixed‑rate notes issued under a shelf registration statement on Form S‑3, with related legal opinions filed as exhibits.
Additional 8‑Ks address governance topics such as the approval of The Procter & Gamble 2025 Stock and Incentive Compensation Plan, voting results from the Annual Meeting of Shareholders, and retirement announcements for senior executives. Earnings‑related 8‑Ks furnish quarterly results, slides used on earnings calls, and notices of webcasts. Together with the company’s proxy statement on Schedule 14A, these filings give a structured view of P&G’s executive compensation framework, board composition, and strategic priorities.
On this page, Stock Titan provides real‑time access to Procter & Gamble’s SEC filings as they appear on EDGAR, along with AI‑powered summaries to help explain the significance of each document. Users can quickly review annual and quarterly reports, current reports on Form 8‑K, and exhibits related to new debt offerings or compensation plans, as well as monitor items such as dividend announcements and shareholder vote outcomes without reading every page of the underlying filings.
Procter & Gamble reported higher sales and earnings for the March 31, 2026 quarter and nine-month period. Quarterly net sales rose to $21.2 billion from $19.8 billion, with organic sales up 3% on modest volume growth, pricing and favorable foreign exchange.
Quarterly net earnings attributable to Procter & Gamble increased to $3.9 billion, and diluted EPS grew to $1.63 from $1.54. For the nine months, net sales reached $65.8 billion and net earnings attributable to Procter & Gamble were $13.0 billion, driving diluted EPS of $5.36 and Core EPS of $5.46.
Gross margin declined on mix, product and packaging investments, tariffs and higher restructuring, partly offset by productivity savings. Operating cash flow was $14.4 billion, with adjusted free cash flow of $11.7 billion and adjusted free cash flow productivity of 92%. The company is executing a $1.5–$2.0 billion restructuring plan and recorded a gain from dissolving the Glad joint venture, while noting potential recovery of about $200 million in previously paid U.S. tariffs.
The Procter & Gamble Company reported third-quarter fiscal 2026 results showing modest growth in a tougher environment. Organic sales rose 3%, driven by 2% higher volume and 1% pricing, with all 10 product categories and 7 regions growing organically.
Core earnings per share were $1.59, up 3% from the prior year, while currency-neutral core EPS of $1.54 was flat. Core gross margin was 50.0% and core operating margin 22.2%, both about 1 percentage point below last year, reflecting cost and mix pressures despite productivity savings.
Adjusted free cash flow productivity reached a strong 82%. For full-year fiscal 2026, the company maintained guidance for organic sales growth of 0%–4%, net sales growth of 1%–5%, core EPS growth of 0%–4%, and all-in EPS growth of 1%–6%, alongside plans for about $10 billion in dividends and $5 billion in share repurchases.
Procter & Gamble reported fiscal 2026 third-quarter net sales of $21.2 billion, up 7%, with organic sales up 3% on 2% higher volume and 1% pricing. Diluted EPS rose 6% to $1.63, aided by a gain from dissolving the Glad joint venture, while core EPS increased 3% to $1.59.
Operating cash flow was $4.0 billion and adjusted free cash flow $3.0 billion, for 82% adjusted free cash flow productivity. The company returned $3.2 billion to shareholders through $2.5 billion in dividends and over $600 million of buybacks, and recently extended its dividend growth streak to 70 consecutive years.
P&G maintained fiscal 2026 guidance for all-in sales growth of 1%–5% and organic sales growth of in-line to up 4%, and kept diluted EPS growth guidance at 1%–6% and core EPS growth at in-line to up 4%, but now expects EPS near the lower end of the ranges due to about $0.25 per-share headwinds from commodities, tariffs, interest and taxes. The company still plans around $10 billion in dividends and about $5 billion of share repurchases in fiscal 2026.
The Procter & Gamble Company announced that its Board of Directors declared an increased quarterly dividend of $1.0885 per share on its Common Stock and Series A and B ESOP Convertible Class A Preferred Stock. The dividend is payable on or after May 15, 2026 to shareowners of record on April 24, 2026.
The company stated this dividend is a 3% increase from the prior quarterly dividend. P&G highlighted that it has paid a dividend for 136 consecutive years and has raised its dividend for 70 consecutive years, underscoring a long-standing commitment to returning cash to shareowners who value steady income.
PROCTER & GAMBLE Co executive Paul Gama has filed an initial ownership report showing his equity interests in the company. As CEO – Health Care, he directly holds 35,950.5707 shares of common stock, plus multiple stock options on common shares with exercise prices such as $113.23 and $139.58 expiring between 2030 and 2033. He also holds various Restricted Stock Units that generally settle in P&G common stock or cash under the company’s retirement programs, and additional common and preferred stock are held indirectly through a retirement plan trustee.
The Vanguard Group filed Amendment No. 12 to Schedule 13G/A reporting 0% beneficial ownership of Procter & Gamble Co common stock and an amount beneficially owned of 0 shares. The filing states this follows an internal realignment: certain Vanguard subsidiaries or business divisions will report ownership separately in reliance on SEC Release No. 34-39538 (January 12, 1998).
The filing is a disclosure of ownership structure changes and notes that the disaggregated entities pursue the same investment strategies previously followed by The Vanguard Group, Inc.
PROCTER & GAMBLE Co director Portman Robert Jones reported an amended equity award. The Form 4/A corrects a prior filing that had shown a grant of 193 restricted stock units under the company’s 2025 Stock and Incentive Compensation Plan; the amended report shows an award of 49 RSUs instead. Following this compensation-related acquisition, his directly held common stock position is 5,065.7148 shares, making the change administrative rather than a new trading decision.
Portman Robert Jones reported acquisition or exercise transactions in this Form 4 filing.
PROCTER & GAMBLE Co director Robert Jones Portman received an equity award of 193 shares of Common Stock on 2026-03-10.
The award consists of Restricted Stock Units granted under The Procter & Gamble 2025 Stock and Incentive Compensation Plan, including dividend equivalents in the form of additional units. Following this grant, he holds 5,209.7148 shares directly.
McEvoy Ashley reported acquisition or exercise transactions in this Form 4 filing.
PROCTER & GAMBLE Co director Ashley McEvoy received an equity award of 161 shares of Common Stock on 2026-03-10. The transaction is coded as a grant or award, not an open-market purchase, with a price per share of $0.0000, indicating compensation rather than cash investment.
Footnotes explain that the award consists of Restricted Stock Units granted under The Procter & Gamble 2025 Stock and Incentive Compensation Plan, and that the total includes dividend equivalents in the form of additional Restricted Stock Units. Following this grant, McEvoy directly holds 5,751.065 shares.
McCarthy Christine M reported acquisition or exercise transactions in this Form 4 filing.
PROCTER & GAMBLE Co director Christine M. McCarthy received an award of 209 shares of Common Stock on March 10, 2026. The filing describes this as a grant or award transaction, with no cash price per share reported.
These shares are in the form of Restricted Stock Units granted under The Procter & Gamble 2025 Stock and Incentive Compensation Plan. The total reported direct holdings after this award are 17,128.6365 shares, which include dividend equivalents granted as additional Restricted Stock Units.